Psyomics adds US healthcare executive Raj Malik to board

Psyomics has appointed veteran US healthcare leader Raj Malik to its board as the digital mental health company expands in the UK and prepares for international growth. The move comes as Psyomics advances its platform, readies biomarker technology and eyes the US as a key market.

Why it matters: - Psyomics is entering a new commercial phase with ambitions beyond the UK. - Raj Malik brings experience in scaling digital health businesses, raising capital and navigating US healthcare markets. - The appointment is designed to support growth, investor engagement and eventual international expansion.

What happened: - Psyomics appointed Raj Malik to its board. - The company made the announcement on September 17, 2026. - Malik will advise CEO Dr Melinda Rees, the senior leadership team and board members on commercial growth, investor engagement and international expansion. - The US is among the markets Psyomics is evaluating for future growth.

The details: - Malik has more than 30 years of experience across digital health, technology, law and business leadership. - He has built and scaled businesses in the US, the UK and other markets. - Malik helped grow Rally Health from launch to $2 billion in revenue before its acquisition by Optum. - His career includes senior roles at companies that were sold to Optum, Google and General Atlantic. - Malik started his career in law as an Assistant Attorney General before becoming an antitrust attorney at White & Case. - Psyomics said that legal and regulatory background gives Malik direct insight into the NHS-facing procurement environment. - Malik is a National Association of Corporate Directors Certified Director and has been inducted into the Dealmakers Hall of Fame. - Psyomics is expanding the use of its digital mental health platform and preparing to launch its biomarker technology. - The company is combining digital mental health assessment with biomarker technology to support clinical decision-making and help people access appropriate care. - Psyomics is focused on growing its UK customer base while proving clinical and operational impact.

Between the lines: - Malik’s addition signals that Psyomics wants more than operational advice; the company is bringing in a board member with a track record of scaling and exiting healthcare businesses. - The emphasis on biomarker technology suggests Psyomics is trying to differentiate itself in a crowded digital mental health market. - The UK remains the immediate priority, but the US is positioned as the most important next expansion opportunity.

What's next: - Psyomics will keep expanding its UK customer base. - The company will work to demonstrate clinical and operational outcomes from its technology. - Psyomics plans to launch its biomarker capability and pursue international opportunities, including in the US. - Malik is expected to help guide growth strategy as the company moves into its next phase.

The bottom line: - Psyomics is betting that an experienced US operator can help turn UK traction into a broader international growth story. - More information